DelveInsight’s “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast–2034” delivers comprehensive analysis of Dry Eye Disease, encompassing historical and projected epidemiology, alongside market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The document highlights investigational therapies, current treatment approaches, therapy-wise market proportion, and market valuation projections from 2020 to 2034. It further examines treatment algorithms, key market drivers and obstacles, and existing unmet requirements, facilitating identification of growth opportunities and evaluation of the market’s overall potential.
To know in detail about the Dry Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Eye Disease Market Forecast-https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Notable Highlights of the Dry Eye Disease Market Report:
In May 2025, AbbVie reported an investigation in which Stage 1 evaluated the safety of AGN-242428 and AGN-231868, how well they are tolerated, and how they move through the body when administered. After the sponsor’s determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 commenced. Stage 2 also evaluated the safety and tolerability of AGN-242428 and AGN-231868, how effective they are in managing dry eye disease (DED), and assessed the plasma and tear exposure of both ophthalmic solutions.
In May 2025, University of Waterloo reported an investigation to evaluate changes in comfort and dryness in symptomatic contact lens (CL) wearers after utilizing Xiidra (lifitegrast 5.0% ophthalmic solution) for 12 weeks.
In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Dry eye disease in the 7MM were nearly 54,695 thousand in 2023.
Among European countries, the United Kingdom possessed the highest diagnosed prevalent cases of Dry eye disease with ~6,112 thousand cases, followed by Germany, which possessed a diagnosed prevalent population of ~5,004 thousand in 2023. On the other hand, Spain possessed the lowest prevalent population (2,064 thousand cases).
In 2023, the Dry eye disease market valuation was highest in the US among the 7MM, accounting for approximately USD 2,739 million which is further anticipated to increase by 2034.
In February 2025, Cambium Bio reported that the FDA approved the protocol for the phase III clinical investigations of elate ocular for managing moderate to severe dry eye disease.
In December 2024, the FDA announced a nationwide recall of a single-use eye drop. Alcon Laboratories recalled one lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count (Lot 10101), following a customer complaint about fungal contamination in a vial. This recall only affects the specified lot of Systane Lubricant Ultra PF eye drops.
In January 2024, Alcon, headquartered in Switzerland, reported the success of its dry eye disease medication AR-15512 in meeting primary endpoints in two Phase III investigations, namely COMET-2 and COMET-3. With encouraging outcomes from these investigations, the organization intends to submit a new drug application (NDA) for AR-15512 to the US Food and Drug Administration (FDA) by mid-2024.
In January 2024, Stuart Therapeutics, a biopharmaceutical organization based in the United States, initiated a Phase III clinical investigation for their drug candidate vezocolmitide (ST-100) targeting individuals with dry eye disease. This randomized, placebo-controlled trial seeks to assess the effectiveness and safety of a single dose of the ophthalmic solution compared to a placebo. The investigation is positioned to enroll 320 participants.
According to an investigation conducted by Farrand et. al, based on weighted estimates, 6.8% of the US adult population was projected to have diagnosed Dry Eye Disease.
One investigation found that 17% of 2,127 individuals visiting a hospital in Japan were diagnosed with dry eyes, while 14.6% in a group of 2,520 older individuals documented symptoms of dry eyes.
Key Dry Eye Disease Companies: Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree/RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon/Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A./PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, AxeroVision, Inc., AxeroVision, Inc., Glaukos Corporation, Oculis, among others
Key Dry Eye Disease Therapies: PL9643, NOV03, CyclASol, MC2-03, among others
The Dry Eye Disease epidemiology based on gender analyzed that females are more affected by Dry Eye Disease than males
Dry Eye Disease Summary
Dry eye disease (DED), also known as dry eye syndrome or keratoconjunctivitis sicca, represents a prevalent and multifactorial disorder characterized by insufficient tear production or excessive tear evaporation, leading to ocular surface inflammation and damage. This disorder results in symptoms including dryness, irritation, redness, burning, a gritty sensation, and blurred vision, which can substantially impact quality of life.
The underlying causes of Dry Eye Disease are varied and can encompass age-related decline in tear production, hormonal changes, autoimmune diseases (like Sjögren’s syndrome), prolonged screen use, environmental factors (such as wind or dry climates), and certain medications. Meibomian gland dysfunction, where the glands responsible for the oily layer of the tear film are obstructed, also represents a common contributor.
Dry Eye Disease Diagnosis involves comprehensive eye examination, encompassing patient history, tear film assessment, and specific tests like Schirmer’s test, tear breakup time (TBUT), and ocular surface staining.
Management of Dry Eye Disease focuses on alleviating symptoms and addressing the underlying causes. Treatment options encompass artificial tears, anti-inflammatory medications (including cyclosporine or lifitegrast), punctal plugs to reduce tear drainage, and lifestyle modifications like increasing humidity and taking regular breaks during screen use. Advanced therapies, encompassing intense pulsed light (IPL) therapy and autologous serum eye drops, may be considered for severe cases. Ongoing research aims to advance more effective treatments and improve understanding of this complex disease.
Get a Free sample for the Dry Eye Disease Market Report – Dry Eye Disease Treatment Market https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Dry Eye Disease Market Outlook
The Dry Eye Disease market is anticipated to expand with the potential introduction of innovative therapies like RGN-259, Tavilermide (MIM-D3), and AR-15512, which could reshape treatment dynamics despite uncertain success rates.
In 2023, the US dominated the market with ~73% of the 7MM, while the UK led in Europe (USD 232M) and Spain possessed the lowest proportion (~USD 80M). Overall, innovation and new approvals are anticipated to drive significant expansion in upcoming years.
The dynamics of the Dry Eye Disease market are anticipated to transform in upcoming years owing to the expected introduction of investigational therapies among others during the forecasted period 2020-2034.
“Of the investigational therapies, MC2-03 (mc2 therapeutics), PL9643 (Palatin Technologies), and many other compelling treatments are anticipated to change the market scenario of Dry Eye Disease in upcoming years.”
Dry Eye Disease (DED), or keratoconjunctivitis sicca, represents a growing market opportunity due to its high prevalence and requirement for better management solutions. Current treatments encompass artificial tears, prescription drugs (CEQUA, EYSUVIS), advanced therapies (LipiFlow), supplements, and specialized interventions for severe cases.
Dry Eye Disease Epidemiology
In 2023, Dry Eye Disease (DED) diagnosed prevalence in the 7MM was ~54.7 million cases. The US represented the highest proportion (41%), followed by the UK (~6.1M) and Germany (~5M), while Spain possessed the lowest (~2M). Japan documented the fewest cases overall (19%) among the 7MM.
In the US, prevalence was higher in females (~13M) compared to males (~9.4M), a gap anticipated to widen by 2034. Mild cases dominated (~11.2M), followed by severe (~4.5M), a trend projected to persist.
By age, the UK documented the highest burden in those 50+ years (~4.9M cases), with lower prevalence in younger groups. This demographic trend is also anticipated to continue through 2034.
Dry Eye Disease Epidemiology Classification:
The Dry Eye Disease market document presents epidemiological analysis for the investigation period 2020–2034 in the 7MM categorized into:
- Total Prevalence of Dry Eye Disease
- Prevalent Cases of Dry Eye Disease by severity
- Gender-specific Prevalence of Dry Eye Disease
- Diagnosed Cases of Episodic and Chronic Dry Eye Disease
Download the report to understand which factors are driving Dry Eye Disease epidemiology trends @ Dry Eye Disease Patient Pool Forecasting-https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Dry Eye Disease Market Drivers
- High Prevalence & Growing Patient Pool – Increasing cases across aging populations and rising diagnosis rates.
- Lifestyle & Environmental Factors – Increased screen time, contact lens usage, pollution, and aging drive higher incidence.
- Unmet Medical Requirements – Limited long-term efficacy of OTC/artificial tears fuels demand for advanced therapies.
- Technological Advancements – Devices like LipiFlow and novel drug delivery systems improving treatment outcomes.
- Pipeline Innovation – Investigational therapies (RGN-259, Tavilermide, AR-15512, etc.) anticipated to transform the treatment landscape.
- Rising Awareness & Diagnosis – More ophthalmologists and optometrists screening for DED, enhancing treatment uptake.
Dry Eye Disease Market Obstacles
- Limited Efficacy of Current Therapies – Existing drugs frequently provide symptomatic relief but not a cure.
- High Treatment Costs – Advanced devices and branded prescription therapies can be expensive.
- Poor Patient Compliance – Frequent dosing and long-term management reduce adherence rates.
- Underdiagnosis & Misdiagnosis – Many individuals mistake symptoms for allergies or aging, delaying proper treatment.
- Generic & OTC Competition – Widespread use of low-cost artificial tears limits adoption of premium therapies.
- Regulatory & Clinical Challenges – Variability in trial endpoints and high failure rates in late-stage pipelines.
Dry Eye Disease Drugs Adoption and Pipeline Advancement Activities
Reproxalap (Aldeyra Therapeutics/AbbVie) represents a first-in-class small-molecule modulator of RASP demonstrating positive late-phase investigation results in >2,400 individuals with a strong safety profile. AbbVie possesses exclusive option rights (Oct 2023).
Tivanisiran (SYL1001, Sylentis/PharmaMar) constitutes an siRNA eye drop targeting TRPV1 to regulate ocular pain and inflammation. Successfully met primary endpoint in the Phase III FYDES investigation (Dec 2023).
Tavilermide (MIM-D3, Mimetogen) represents a cyclic peptidomimetic and TrkA receptor agonist mimicking NGF, promoting ocular lubrication. Demonstrated consistent efficacy in Phase II/III investigations and is under Phase III evaluation.
AR-15512 (Alcon/Aerie Pharmaceuticals) constitutes a TRPM8 agonist activating cold-sensing receptors to relieve symptoms. Phase III COMET-2 and COMET-3 investigations met primary endpoints; FDA NDA filing anticipated mid-2024.
RP101 (Redwood Pharma) represents a hormonal therapy for postmenopausal women with moderate-to-severe DED, restoring local estrogen to improve tear film. Despite positive Phase II outcomes, Redwood faces financial challenges and plans to sell the asset via auction.
To know more about Dry Eye Disease treatment, visit @ Dry Eye Disease Medication and Companies-https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Dry Eye Disease Companies
Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree / RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon / Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A. / PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd. / Daewoong Pharmaceutical Co., Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, Glaukos Corporation, Oculis, among others
Coverage of the Dry Eye Disease Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Dry Eye Disease Companies: Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., RegeneRx Biopharmaceuticals, Inc., Alcon Inc., Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech S.A., Senju Pharmaceutical Co., Ltd., Sylentis, S.A., Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma Ltd., Glaukos Corporation, Oculis Holding AG, among others.
- Key Dry Eye Disease Therapies: PL9643, NOV03, CyclASol, MC2-03, among others
- Dry Eye Disease Therapeutic Evaluation: Dry Eye Disease current marketed and Dry Eye Disease investigational therapies
- Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market obstacles
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry tactics
- Dry Eye Disease Unmet Requirements, KOL’s perspectives, Analyst’s perspectives, Dry Eye Disease Market Access and Reimbursement
Do you know how market launch of investigational therapies will be impacting the Dry Eye Disease market CAGR? Download sample report @ Dry Eye Disease clinical trials and fda approvals-https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr
Table of Contents
- Dry Eye Disease Market Report Introduction
- Executive Summary for Dry Eye Disease
- SWOT analysis of Dry Eye Disease
- Dry Eye Disease Patient Share (%) Overview at a Glance
- Dry Eye Disease Market Overview at a Glance
- Dry Eye Disease Disease Background and Overview
- Dry Eye Disease Epidemiology and Patient Population
- Country-Specific Patient Population of Dry Eye Disease
- Dry Eye Disease Current Treatment and Medical Practices
- Dry Eye Disease Unmet Needs
- Dry Eye Disease Emerging Therapies
- Dry Eye Disease Market Outlook
- Country-Wise Dry Eye Disease Market Analysis (2020–2034)
- Dry Eye Disease Market Access and Reimbursement of Therapies
- Dry Eye Disease Market Drivers
- Dry Eye Disease Market Barriers
- Dry Eye Disease Appendix
- Dry Eye Disease Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight represents a leading Healthcare Business Consultant and Market Research organization focused exclusively on life sciences. It supports Pharma companies by delivering comprehensive end-to-end solutions to enhance their performance.
It also provides Healthcare Consulting Services, which benefit in market analysis to accelerate business expansion and overcome challenges with a practical methodology.
Contact Us
Kanishk
kkumar@delveinsight.com
